Medical Management


In addition to the preventative benefits of appropriate medication in high-risk patients with diabetes and/or vascular compromise, working with a patient’s primary care provider to ensure medical optimization of comorbid conditions is a cornerstone of preoperative management to help reduce the risk of postoperative complications. Accordingly, we have a compiled a brief reference resource list ranging from recent studies on antithrombotic medications and lipid-lowering therapies to the latest meta-analyses and literature on hypertension and diabetes management.

Antithrombotic therapy

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial.

Anand SS, Bosch J, Eikelboom JW, et al.Lancet. 2018;391(10117):219-229.
Visit Resource

Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial.

Anand SS, Caron F, Eikelboom JW, et al.J Am Coll Cardiol. 2018;71(20):2306-2315.
Visit Resource

Safety and efficacy of vorapaxar in secondary prevention of atherosclerotic disease: a meta-analysis of randomized control trials.

Sharma A, Helft G, Garg A, et al.Int J Cardiol. 2017;227:617-624.
Visit Resource

Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease.

Bonaca MP, Bhatt DL, Storey RF, et al.J Am Coll Cardiol. 2016;67(23):2719-2728.
Visit Resource

Peripheral revascularization in patients with peripheral artery disease with vorapaxar: insights from the TRA 2oP-TIMI 50 trial.

Bonaca MP, Creager MA, Olin J, et al.JACC Cardiovasc Interv. 2016;9(20):2157-2164.
Visit Resource

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials.

Antithrombotic Trialists’ (ATT) Collaboration; Baigent C, Blackwell L, Collins R, et al. Lancet. 2009;373(9678):1849-60.
Visit Resource

Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial.

Critical Leg Ischaemia Prevention Study (CLIPS) Group; Catalano M, Born G, Peto R. J Intern Med. 2007;261(3):276-84.
Visit Resource
Lipid-Lowering Therapy

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Grundy SM, Stone NJ, Bailey AL, et al.Circulation. 2019;139(25):e1082-e1143.
Visit Resource

Association of statin dose with amputation and survival in patients with peripheral artery disease.

Arya S, Khakharia A, Binney ZO, et al.Circulation. 2018;137(14):1435-1446.
Visit Resource

Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease.

Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenrejch PA.JAMA Cardiol. 2017;2(1):47-54.
Visit Resource

High-intensity statin therapy is associated with improved survival in patients with peripheral artery disease.

Foley TR, Singh GD, Kokkinidis DG, et al.J Am Heart Assoc. 2017;6(7):e005699.
Visit Resource

Use of angiotensin-converting enzyme inhibitors and freedom from amputation after lower extremity revascularization

Kray JE, Dombrovskiy VY, Vogel TR.Vasc Health Risk Manag. 2017;13:269-274.
Visit Resource

Intensive vs. standard blood pressure control and cardiovascular disease outcomes in adults aged > 75 years: a randomized clinical trial.

Williamson JD, Supiano MA, Applegate WB, et al.JAMA. 2016;315(24):2673-82.
Visit Resource

Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the justification for use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

Ridker PM, MacFadyen J, Libby P, Glynn RJ.Am J Cardiol. 2010;106(2):204-9.
Visit Resource

Lipid-lowering for peripheral arterial disease of the lower limb.

Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC.Cochrane Database Syst Rev. 2007;2007(4):CD000123. doi: 10:1002/14651858.CD000123.pub2
Visit Resource

Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: a meta-analysis of randomized controlled trials.

Manapurathe DT, Krishna SM, Dewdney B, Moxon JV, Biros E, Golledge J.PLoS One. 2017;12(6):e0178713. doi: 10.1371/journal.pone.0178713. eCollection 2017.
Visit Resource

6. Glycemic targets: Standards of Medical Care in Diabetes-2021.

American Diabetes Association.Diabetes Care. 2021;44(Suppl 1):S73-S84.
Visit Resource

Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials.

Li D, Yang JY, Wang T, Shen S, Tang H.Diabetes Metab. 2018;44(5):410-414.
Visit Resource

CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes.

Neal B, Perkovic V, Mahaffey KW, et al;N Engl J Med. 2017;377(7):644-57.
Visit Resource
Pain Management

Estimating the effect of intravenous acetaminophen for postoperative pain management on length of stay and inpatient hospital costs.

Shaffer EE, Pham A, Woldman RL, et al.Adv Ther. 2017;33(12):2211-2228.
Visit Resource

Multimodal analgesia, current concepts, and acute pain considerations.

Helander EM, Menard BL, Harmon CM, et al.Curr Pain Headache Rep. 2017;21(1):3.
Visit Resource